Middle East Cystic Fibrosis Association MECFA

MECFA Blog

Genetic research pilot study by Delhi hospital finds ‘unexpected results’

For the first time a high carrier frequency of 4.5% (9 per 200) for Cystic Fibrosis (CF) has been revealed, it claimed. A genetic...

Screening of 200 people finds 4.5% are carriers of cystic fibrosis gene: Study

A carrier frequency of 9 in 200 persons, as was found in the pilot study by doctors from Delhi’s Sir Ganga Ram Hospital, will mean a...

PHCC urges patients with chronic conditions to get flu vaccine

The Peninsula Doha: Patients with chronic conditions have been urged to ensure that they are vaccinated against the flu this year. Flu...

Trikafta, cystic fibrosis ‘miracle drug’, one step closer to being approved in Canada

Canadians living with cystic fibrosis (CF) are in celebration mode, as what’s been described as a life-saving miracle treatment is now a...

Home Monitoring of Lung Health Possible With NuvoAir System, Studies Report

The NuvoAir Home platform — NuvoAir’s respiratory support system for people with lung diseases — allows adults and children with cystic...

Bronchitol Approved As Add On Therapy For Cystic Fibrosis Patients

The Food and Drug Association has approved Chiesi's Bronchitol (mannitol) as an inhalation powder for the treatment of cystic fibrosis in...

ROLE OF MUCUS IN CYSTIC FIBROSIS PATIENTS, A STUDY REVEALS

Cystic fibrosis (CF) is an inherited disorder that primarily affects the lungs, digestive system, and other organs of the body. Usually,...

Respiratory Care Teams Are the MVPs of CF Care

As a person with cystic fibrosis, I’ve formed close-knit relationships with care providers in multiple disciplines. Before my double-lung...

enGene Receives Funding Through Cystic Fibrosis Foundation's Path to a Cure

BOSTON and MONTRÉAL, Oct. 29, 2020 /PRNewswire/ - enGene Inc., a biotechnology company developing non-viral gene therapies for local...

Preclinical Work Supports ELX-02, Potential Treatment for Nonsense Mutations

Eloxx Pharmaceuticals presented preclinical safety and efficacy data supporting ELX-02, its investigational treatment for cystic fibrosis...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p